Trial · NCT03657641
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
NCT03657641, Phase 1, Phase 2, Active not recruiting, University of Southern California
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer. Trials, record NCT03657641. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03657641
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
- NCT number
- NCT03657641
- Status
- Active not recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 73 participants, actual
- Lead sponsor
- University of Southern California
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic
- Interventions
- Pembrolizumab, Regorafenib
- First posted
- 2018-09-05
- Last updated
- 2026-06-16
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients With Dose Modification Due to Toxicity | At the end of Course 1 (each course is 21 days) | Number of patients that required a dose modification while on study treatment, due to a Dose limiting toxicity (DLT), during Phase I and Phase II. DLT was evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03 and is defined in the study protocol section 6.2. |
| Primary | Progression-free Survival (PFS) (Phase II) | At first observation of disease progression or death whichever comes first, up to 3 years and 8 months. | PFS will be calculated from the start of treatment (day 1 of cycle 1) to the first observation of disease progression or death whichever comes first, or to the latest follow up. Kaplan Meier curves will be used for PFS plot. Medians of PFS and their 95% CI confidence intervals will be given. |
| Primary | Overall Survival (OS) | At last date known to be alive, up to 3 years and 8 months. | OS will be calculated from the start of treatment (day 1 or cycle 1) to death from any cause. Kaplan Meier curves will be used to OS plot. Medians and their 95%CI confidence intervals will be given. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA014089 | University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG) | LERMAN, CARYN | UNIVERSITY OF SOUTHERN CALIFORNIA | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03657641
GET https://conductscience.org/api/trials/v1/NCT03657641/registered